nav button
rss facebook twitter

About AtheroNova

AtheroNova Inc. is a biotechnology company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans. Cardiovascular plaque reduction – the holy grail of cardiovascular research1 – is our business.  Our lead compound, AHRO-001, has demonstrated remarkable plaque reduction in animals. We have shown a strong safety and tolerability profile for AHRO-001 in a Phase I clinical trial in humans.  Our current corporate focus is the preparation and filing of an IND with the US Food & Drug Administration for clinical development in the United States and rest of the world. Atherosclerosis and its complications cost consumers more than $38 billion annually in the United States alone.

Recent News

Read More

Company Presentation

Investor Presentation

Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

IR Calendar